Impact of sarcopenia (Sp) on early dose-limiting toxicity (DLT) and acute vascular toxicity in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving sunitinib (SUT).
O. Huillard
No relevant relationships to disclose
O. Mir
Consultant or Advisory Role - Roche (U); SERVIER (U)
N. Barry Delongchamps
No relevant relationships to disclose
B. Blanchet
No relevant relationships to disclose
B. Knebelmann
No relevant relationships to disclose
P. Boudou-Rouquette
No relevant relationships to disclose
R. Coriat
No relevant relationships to disclose
B. Debre
No relevant relationships to disclose
J. Durand
Consultant or Advisory Role - Merck (U)
T. Flam
No relevant relationships to disclose
M. Peyromaure
No relevant relationships to disclose
M. Zerbib
No relevant relationships to disclose
S. Ropert
Consultant or Advisory Role - Roche (U)
F. Goldwasser
Consultant or Advisory Role - Amgen (U); Bayer (U); Pfizer (U)